TerminatedPhase 3NCT00625898
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
Studying Cerebrotendinous xanthomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NSABP Foundation Inc
- Principal Investigator
- Norman Wolmark, MDNSABP Foundation Inc
- Intervention
- Docetaxel(drug)
- Enrollment
- 3509 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2008 – 2014
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Clearview Cancer Institute-Decatur, Decatur, Alabama, United States
- Clearview Cancer Institute, Huntsville, Alabama, United States
- Clearview Cancer Institute- Huntsville, Huntsville, Alabama, United States
- Northern Arizona Hematology & Onclogy Associates, Flagstaff, Arizona, United States
- Northern Arizona Hematology & Oncology Associates, Sedona, Arizona, United States
- Central Hematology/Oncology Medical Group, Inc., Alhambra, California, United States
- Comprehensive Blood and Cancer Center, Bakersfield, California, United States
- Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States
- Kaiser Permanente-Bellflower, Bellflower, California, United States
- Providence Saint Joseph Medical Center, Burbank, California, United States
- Hematology-Encinitas, Encinitas, California, United States
- Scripps Clinic Encinitas, Encinitas, California, United States
- Kaiser Permanente-Fontana, Fontana, California, United States
- St. Jude Heritage Healthcare, Fullerton, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Cancer International Research Group (CIRG) · Hoffmann-La Roche · Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00625898 on ClinicalTrials.govOther trials for Cerebrotendinous xanthomatosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07510802Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBCBeijing Biotech
- RECRUITINGPHASE1NCT07162038Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell TransplantationNational Cancer Institute (NCI)
- RECRUITINGNANCT06790225Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)Esbjerg Hospital - University Hospital of Southern Denmark
- RECRUITINGPHASE2NCT05909059CAR T-cell Therapy in Patients With Renal DysfunctionNorthside Hospital, Inc.
- RECRUITINGPHASE2NCT06042569Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialCity of Hope Medical Center
- RECRUITINGPHASE1, PHASE2NCT06594640R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05748197A Study of ADCLEC.syn1 in People With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT05883852EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerFudan University